GSK2879552 Struktur

GSK2879552

Bezeichnung:GSK2879552

CAS-Nr1401966-69-5

Englisch Name:GSK2879552

CBNumberCB42739119

SummenformelC23H28N2O2

Molgewicht364.48

MOL-Datei1401966-69-5.mol

GSK2879552 physikalisch-chemischer Eigenschaften

Siedepunkt	534.2±50.0 °C(Predicted)
Dichte	1.20±0.1 g/cm3(Predicted)
storage temp.	-20°C
Löslichkeit	Soluble in DMSO (up to 25 mg/ml) or in Water (up to at least 25 mg/ml)
pka	4.03±0.10(Predicted)
Aggregatzustand	solid
Farbe	White
Stabilität	Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 3 months.

Gefahreninformationscode (GHS)

GSK2879552 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
GSK2879552 (1401966-65-5, free base) is potent, selective, and irreversible inhibitor of Lysine Demethylase 1 (LSD1) via covalent modification of the LSD1 cofactor FAD (Ki = 1.7 μM). It is selective for LSD1 over the closely related LSD2, MAO-A, MAO-B, and the FAD dependent enzymes D-amino acid oxidase and glutathione reductase. Tested against a panel of 165 cancer cell lines, GSK2879552 inhibited the proliferation of 9 small cell lung carcinoma lines and 20 AML cell lines.
Definition
ChEBI: GSK2879552 is a member of the class of piperidines that is piperidine substituted by (4-carboxyphenyl)methyl and {[(1R,2S)-2-phenylcyclopropyl]amino}methyl groups at positions 1 and 4, respectively. It is a potent and irreversible inhibitor of lysine specific demethylase 1 (LSD1, also known as KDM1A). It was under clinical investigation for the treatment of acute myeloid leukaemia and small cell lung carcinoma. It has a role as an EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor and an antineoplastic agent. It is a member of benzoic acids, a monocarboxylic acid, a member of piperidines, a member of cyclopropanes, a tertiary amino compound, a secondary amino compound and a member of benzenes.
in vitro
six days of gsk2879552 treatment resulted in potent anti-proliferative growth effects in 19 of 25 aml cell lines representing a range of aml subtypes. treating for longer time periods revealed sensitivity in all aml cell lines. aml blast colony forming ability was also inhibited in 4 of 5 bone marrow samples derived from primary aml patient samples [1].
in vivo
after 17 days of gsk2879552 treatment, control mice had 80% gfp+ cells in the bone marrow whereas treated mice had only 2.8% gfp positive cells, and the treated animals survived weeks beyond control mice [1].
Einzelnachweise
1) Mohammad?et al.?(2015),?A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC; Cancer Cell?28?57

GSK2879552 Upstream-Materialien And Downstream Produkte

GSK2879552 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Send Inquriy